Hardin Leyla Tahrani, Xiao Nan
Department of Biomedical Sciences at the Arthur A. Dugoni School of Dentistry, University of the Pacific, San Francisco, 94103 CA, USA.
Int J Cell Biol. 2022 Oct 29;2022:1645366. doi: 10.1155/2022/1645366. eCollection 2022.
As many parts of the world continue to fight the innumerable waves of COVID-19 infection, SARS-CoV-2 continues to sculpt its antigenic determinants to enhance its virulence and evolvability. Several vaccines were developed and used around the world, and oral antiviral medications are being developed against SARS-CoV-2. However, studies showed that the virus is mutating in line with the antibody's neutralization escape; thus, new therapeutic alternatives are solicited. We hereby review the key role that miRNAs can play as epigenetic mediators of the cross-talk between SARS-CoV-2 and the host cells. The limitations resulting from the "virus intelligence" to escape and antagonize the host miRNAs as well as the possible mechanisms that could be used in the viral evasion strategies are discussed. Lastly, we suggest new therapeutic approaches based on viral miRNAs.
随着世界许多地区继续应对新冠病毒感染的无数浪潮，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）继续塑造其抗原决定簇，以增强其毒力和进化能力。世界各地研发并使用了几种疫苗，同时也在开发针对SARS-CoV-2的口服抗病毒药物。然而，研究表明，该病毒正在按照抗体的中和逃逸进行变异；因此，人们寻求新的治疗选择。在此，我们综述了微小RNA（miRNAs）作为SARS-CoV-2与宿主细胞之间相互作用的表观遗传介质可能发挥的关键作用。讨论了“病毒智能”逃避和拮抗宿主miRNAs所带来的局限性，以及病毒逃避策略中可能使用的机制。最后，我们提出了基于病毒miRNAs的新治疗方法。
